2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Cancer of the Breast: new trials by email Literature Review of Cancer of the Breast trials Research Report on Cancer of the Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) nab-Paclitaxel, Carboplatin, Gemcitabine - Breast Tumor, Breast Cancer | Phase 2 / Phase 3 | Completed | Celgene | 191 | 2013-09-26 | 2019-02-21 |
| A Phase III Trial For Patients With Metastatic Breast Cancer gemcitabine, docetaxel, capecitabine - Breast Cancer, Breast Neoplasms | Phase 3 | Completed | Eli Lilly and Company | 475 | 2002-02-01 | 2009-12-24 |
Breast Neoplasms (2) · Triple Negative Breast Neoplasms (1)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Gemcitabine (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Carboplatin (1) · Docetaxel (1)
Celgene (1) · Eli Lilly and Company (1)
Australia (2) · Brazil (2) · United States (2) · Argentina (1) · Austria (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Mexico (1) · Portugal (1) · Puerto Rico (1) · South Korea (1) · Spain (1)